Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biocult Strong
- Development stage
- Unknown
- Lead developer
- Homeosyn Italia
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Biocult Strong is an investigational multi-strain probiotic formulation developed by Homeosyn S.r.l. for the treatment of anxiety and obesity-related psychological symptoms. Classified as a live biotherapeutic product (LBP), it contains a specific mixture of eight live bacterial strains: *Streptococcus thermophilus* (SGSt01), *Bifidobacterium animalis subsp. lactis* (SGB06), *Bifidobacterium bifidum* (SGB02), *Lactobacillus delbrueckii spp. bulgaricus* (DSM 20081), *Lactococcus lactis subsp. lactis* (SGLc01), *Lactobacillus acidophilus* (SGL11), *Lactobacillus plantarum* (SGL07), and *Lactobacillus reuteri* (SGL01). The formulation targets the microbiota-gut-brain axis and the hypothalamic-pituitary-adrenal (HPA) axis, modulating the production of neuroactive compounds such as serotonin and gamma-aminobutyric acid (GABA) to reduce cortisol levels and alleviate anxiety. Clinical trials, including NCT01890070, have demonstrated that a three-week administration of the suspension can significantly reduce Hamilton Anxiety Rating Scale scores and improve body composition parameters in women with obesity or normal-weight obesity syndrome.
- Brand names
- Biocult Strong
- Other names
- Psychobiotics oral suspensionPOS
Beyond the preview
Go deeper on Biocult Strong.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biocult Strong.